Présentations du GINECO à l'ASCO 2023

Par le biais de cette page, vous pouvez accéder à l'ensemble des présentations du GINECO à l'ASCO (American Society of Clinical Oncology).


Le GINECO à l'ASCO 2022


Page d'accès aux présentations du GINECO au congrès de l'ASCO qui s'est tenu du 2 au 6 juin 2023

Comme les années précédentes le GINECO était, cette année encore, très présent à l'ASCO avec :


Clinical Science Symposium :


  • SHAPE / GCIG : An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-rik early-stage cervical cancer (LRESCC). 



Gynecological cancer oral session :


  • COLIBRI / GINECO-CE108b :  In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study


  • DUO-O / ENGOT-ov46 :  Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.



 Late Breaking gynecological cancer oral session : 


  • MIRASOL / ENGOT-ov45 :  Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.



Gynecological cancer poster discussion :


  • RAMP201 / ENGOT-ov60 :  Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).


  • NIQOLE / GINECO-ov239b : Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study. 


  •  PAOLA-1 : BRCA1 and RAD51 Methylation impact on advanced ovarian cancer patient outcome


Metastatic breast cancer oral session :


  • PADA-1 / UGBG-GINECO :  Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial


Haut de page
Modifié le 26-06-2019 17:22:26